Vobarilizumab (ALX-0061) is a humanized bispecific monoclonal antibody that targets both the interleukin-6 receptor (IL-6R) and human serum albumin (ALB) with a dissociation constant (Kd) of 0.19 pM. This antibody features distinct domains: one that binds to IL-6R and another that binds to human serum albumin. The dual specificity of Vobarilizumab allows for enhanced targeting and retention in the human body, making it a valuable tool in the study of inflammatory autoimmune conditions, including rheumatoid arthritis. This antibody's unique configuration and high affinity make it ideal for research applications focused on the pathogenesis and treatment strategies of such diseases.
Vobarilizumab (ALX-0061) is a humanized bispecific monoclonal antibody that targets both the interleukin-6 receptor (IL-6R) and human serum albumin (ALB) with a dissociation constant (Kd) of 0.19 pM. This antibody features distinct domains: one that binds to IL-6R and another that binds to human serum albumin. The dual specificity of Vobarilizumab allows for enhanced targeting and retention in the human body, making it a valuable tool in the study of inflammatory autoimmune conditions, including rheumatoid arthritis. This antibody's unique configuration and high affinity make it ideal for research applications focused on the pathogenesis and treatment strategies of such diseases.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
